2013 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/13/13AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. BATON-CRC, led by Astellas, is an open-label, randomized Phase 2 study wit... 
Printer Friendly Version
11/07/13AVEO Reports Third Quarter 2013 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results. “We continue to execute on the strategy we outlined earlier this year, focusing our resources where the unique insights derived from our proprietary Human Response Platform™ will enable the potential development of therapies for biomarker-defined patient populations,” said Tuan Ha-Ngoc, president and chief... 
Printer Friendly Version
09/04/13AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 4, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the ... 
Printer Friendly Version
08/09/13AVEO Oncology to Present at the Canaccord Genuity 33rd Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.m. (ET) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcas... 
Printer Friendly Version
08/08/13AVEO Reports Second Quarter 2013 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 8, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results. “We are moving forward as an organization and are firmly focused on executing our revised business strategy,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “We continue to advance our programs in clinical development, including tivozanib in colorectal and breast cancer, which are currently... 
Printer Friendly Version
06/10/13AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 10, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) informing the company that the FDA will not approve in its present form the New Drug Application (NDA) for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC). In the letter, the FDA stated th... 
Printer Friendly Version
06/04/13AVEO Oncology Announces Strategic Restructuring
AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring that will refocus the company’s efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advancing key pipeline and preclinical assets. This restructuring is expected to extend the company’s cash runway for at ... 
Printer Friendly Version
05/15/13AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--May. 15, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in ... 
Printer Friendly Version
05/02/13AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial (1... 
Printer Friendly Version
05/02/13Trading of AVEO Common Stock Halted
FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma AVEO Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May 2, 2013. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) meets today to discuss the New Drug ... 
Printer Friendly Version
04/29/13AVEO Reports First Quarter 2013 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported first quarter 2013 financial results. In lieu of a quarterly financial update conference call, the AVEO management team expects to host a conference call on May 2, 2013 following the review by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) of the company’s New Drug Application (NDA) for tivozanib. “AVEO has seve... 
Printer Friendly Version
03/06/13AVEO Oncology to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.m. (ET) in Miami. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast will ... 
Printer Friendly Version
02/27/13AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Oncologic Drugs Advisory Committee Meeting Scheduled for May 2, 2013 CAMBRIDGE, Mass. & NORTHBROOK, Ill.--(BUSINESS WIRE)--Feb. 27, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's New Drug Application (ND... 
Printer Friendly Version
02/20/13AVEO Oncology to Present at the 2013 RBC Capital Markets’ Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A repla... 
Printer Friendly Version
02/13/13AVEO Reports 2012 Financial Results and Highlights Recent Accomplishments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 13, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2012 financial results and reviewed key recent accomplishments. “We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO-1, receiving the FDA’s acceptance of the NDA submission and expanding tivozanib clinical development into patients with triple negative breast cancer,”... 
Printer Friendly Version
02/12/13AVEO and Astellas Report Final Overall Survival Results from TIVO-1
Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Feb. 12, 2013-- AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma ... 
Printer Friendly Version
01/31/13AVEO Oncology Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Conference Call
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2013-- AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013. The AVEO management team will host a conference call discussing the company’s financial results, recent developments and detailed TIVO-1 findings on Wednesday, February 13, 2013 at 10:00 a.m. (ET)... 
Printer Friendly Version
01/29/13AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Jan. 29, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida. The schedul... 
Printer Friendly Version
01/24/13AVEO Announces Closing of Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 7,667,050, comprised of 6,667,000 shares of common stock initially offered and an additional 1,000,050 shares of common stock sold pursuant to the underwriters' exercise of their over-allotment option, at the public offering price of $... 
Printer Friendly Version
01/22/13AVEO Announces Exercise of Over-Allotment Option for Recent Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of the option granted to the underwriters, at the public offering price of $7.50 per share. All of the shares are being sold by AVEO. As a result, the company expects to issue a total of 7,... 
Printer Friendly Version
01/17/13AVEO Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 17, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.50 per share to the public. All of the shares are being sold by AVEO. The gross proceeds to AVEO from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions, and other estimated ... 
Printer Friendly Version
01/16/13AVEO Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 16, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering, with RBC Capital Markets, LLC and Canaccord Genuity Inc. acting as co-lead managers. AVEO intends to ... 
Printer Friendly Version